Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer.

Yoshinori MoriTomoya KataokaMasahide EbiKazunori AdachiYoshiharu YamaguchiNoriyuki HayashiYoshikazu HirataSatoshi SobueRyo IshiharaYuta SuzukiTakashi MizushimaYusuke InoueIzumi HasegawaSatoshi OnoAtsuyuki HiranoYoshihide KimuraKyoji SenoKeiji OzekiTakaya ShimuraEiji Kubota

Published in: Journal of gastrointestinal cancer (2021)

SOX100 combined with trastuzumab was effective with a favorable safety profile in patients with HER2-positive AGC.

Keyphrases

phase ii
clinical trial
epidermal growth factor receptor
open label
transcription factor
stem cells
metastatic breast cancer
phase iii
neoadjuvant chemotherapy
double blind
randomized controlled trial
placebo controlled
radiation therapy